Strategies to manage retinoblastoma in developing countries

Chantada, Guillermo; Qaddoumi, Ibrahim; Canturk, Serife; Khetan, Vikas; Ma, Zhuang; Kimani, Kahaki; Yeniad, Barış; Sultan, Iyad; Sitorus, Rita S; Taçyıldız, Nurdan; Abramson, David H.

doi:10.1002/pbc.22843

Cited by 128 publications

(126 citation statements)

References 65 publications

Supporting

Mentioning

109

Contrasting

Unclassified

Order By: Relevance

“…However, its survival rates in developing countries are significantly lower. Late diagnosis, poor treatment compliance and limitations for access to treatment, leading to extraocular dissemination, are the major causes for these poor results (Chantada et al 2011;Navo et al 2012).…”

Section: Introductionmentioning

confidence: 99%

Immunoreactivity of the 14F7 Mab raised against N‐Glycolyl GM3 Ganglioside in retinoblastoma tumours

Torbidoni

Scursoni

Camarero

et al. 2014

Acta Ophthalmologica

View full text Add to dashboard Cite

ABSTRACT.Introduction: The identification of molecules expressed selectively on the surface of retinoblastoma cells would allow applying targeted therapies. The Ganglioside, N-Glycolyl-GM3 (NeuGc-GM3), is an attractive candidate, as it has been detected in other paediatric neuroectodermic tumours, and it is not expressed in human normal tissues. The 14F7 antibody recognizes specifically the ganglioside NeuGc-GM3. Purpose: To characterize the expression of NeuGc-GM3 in retinoblastoma cell lines and in retinoblastoma tumours using the 14F7 monoclonal antibody. Methods: We studied WERI-Rb1 and Y79 cell lines, 24 retinoblastoma primary tumours from unilateral and bilateral cases and two bone marrow biopsies from metastatic retinoblastoma. Tumours were classified into three groups: non-invasive (n = 13), invasive (n = 9) and metastatic (n = 2). Three eyes enucleated because of non-tumoural conditions were used as controls. Cell lines and tumour sections were studied by immunohistochemistry using the 14F7 antibody. NeuGc-GM3 expression was evaluated by analysing the percentage of positive tumoural cells and the staining intensity. These parameters were analysed comparatively among the three groups. Results: Both retinoblastoma cell lines showed immunoreactivity to NeuGc-GM3 but WERI-Rb1 presented higher intensity than Y79. All the tumours studied showed strong immunoreactivity to NeuGc-GM3 with no significant differences among groups. In both bone marrow specimens, NeuGc-GM3 immunoreactivity was observed in retinoblastoma cells. In bilaterally enucleated cases, NeuGc-GM3 immunoreactivity was not altered before and after chemotherapy. Non-tumoural retinas were negative. Conclusions: NeuGc-GM3 is highly expressed in retinoblastoma cell lines, tumours and metastatic cells to the bone marrow, and it is not detectable in control eyes. There were no significant differences in the immunoreactivity to 14F7 among tumours from different disease stages. Its immunoreactivity did not change after chemotherapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Immunoreactivity of the 14F7 Mab raised against N‐Glycolyl GM3 Ganglioside in retinoblastoma tumours

Torbidoni

Scursoni

Camarero

et al. 2014

Acta Ophthalmologica

View full text Add to dashboard Cite

show abstract

“…There has been only 1 previous report on the use of 18 F-FDG PET alone without CT in 4 patients with retinoblastoma (6). In developing countries, 25%-40% of all retinoblastoma patients belong to IRSS stage III, because of delayed presentation and diagnosis (7,8). We estimate that around 7,000-10,000 IRSS stage III children are diagnosed every year in developing countries, and more than half of them would die because of the disease.…”

mentioning

confidence: 99%

Role of PET/CT in Staging and Evaluation of Treatment Response After 3 Cycles of Chemotherapy in Locally Advanced Retinoblastoma: A Prospective Study

Radhakrishnan¹,

Kumar²,

Malhotra³

et al. 2012

J Nucl Med

View full text Add to dashboard Cite

The present study prospectively evaluated the role of 18 F-FDG PET/CT for staging, neoadjuvant chemotherapy response evaluation, and final outcome assessment in International Retinoblastoma Staging System (IRSS) stage III retinoblastoma. Methods: Twenty-five consecutive IRSS stage III patients, with a median age of 3 y, were prospectively enrolled after ethics approval. All patients received neoadjuvant chemotherapy followed by enucleation, radiotherapy, and adjuvant chemotherapy. PET/CT was performed at baseline (PET/CT-1) and after 3 cycles of neoadjuvant chemotherapy (PET/CT-2). All 25 patients underwent PET/CT-1, and 21 of 25 patients underwent PET/CT-2. PET/CT-1 was compared with routine staging, and response on PET/CT-2 was assessed by criteria from the European Organization for Research and Treatment of Cancer response. Eventfree survival (EFS) and overall survival (OS) were calculated using Kaplan-Meier survival analysis, and differences between the groups were compared using log-rank test. A P value of 0.05 or less was considered significant. Results: Increased 18 F-FDG uptake was noted in primary extraocular tumor in all patients, except 5 with bilateral retinoblastoma (one eye with advanced and the other eye with intraocular disease) in whom the intraocular tumor did not show 18 F-FDG uptake. Five of 22 IRSS stage IIIA patients with clinically negative cervical lymph node involvement were found to have uptake in cervical lymph nodes on PET/CT-1, and 2 of 3 IRSS stage IIIB patients with pathologically confirmed cervical lymph node involvement did not show any uptake in the involved lymph nodes. No significant difference in EFS and OS was seen between IRSS stage IIIA and IIIB patients using routine staging or PET/CT staging (P $ 0.05); however, there was a trend toward better OS in patients with IRSS stage IIIB disease on PET/CT (P 5 0.065). There was no significant discordance between routine staging and PET/CT staging (P 5 0.256). The 8 patients with optic nerve uptake had lower EFS (P 5 0.0001) and OS (P 5 0.0009) than did 17 patients without optic nerve uptake on PET/CT-1. The 17 patients with complete response or partial response had better EFS (P 5 0.042) and OS (P 5 0.026) than did the 4 patients with progressive disease on PET/CT-2. Conclusion: Optic nerve uptake at baseline on PET/CT and response after neoadjuvant chemotherapy according to criteria from the European Organization for Research and Treatment of Cancer are strong predictors of EFS and OS in IRSS stage III retinoblastoma.

show abstract

“…In developing countries, the high costs and sometimes unavailability of, or limited training in, eye salvage treatment modalities, and the immaturity of health insurance systems, make attempt at eye salvage a tantalizing, hopeful, but difficult option for the child, the family and the treating physician [4,11,12]. Enucleation carries social stigma in some cultures, and physicians may experience difficulty in convincing parents (the decision makers for the child) to consent [13].…”

Section: Introductionmentioning

confidence: 97%

Socioeconomic and psychological impact of treatment for unilateral intraocular retinoblastoma

Soliman

Dimaras

Souka

et al. 2015

Journal Français d'Ophtalmologie

View full text Add to dashboard Cite

Strategies to manage retinoblastoma in developing countries

Cited by 128 publications

References 65 publications

Immunoreactivity of the 14F7 Mab raised against N‐Glycolyl GM3 Ganglioside in retinoblastoma tumours

Immunoreactivity of the 14F7 Mab raised against N‐Glycolyl GM3 Ganglioside in retinoblastoma tumours

Role of PET/CT in Staging and Evaluation of Treatment Response After 3 Cycles of Chemotherapy in Locally Advanced Retinoblastoma: A Prospective Study

Socioeconomic and psychological impact of treatment for unilateral intraocular retinoblastoma

Contact Info

Product

Resources

About